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Introduction
The human leucine rich, glioma inactivated 1 (LGI1) gene appears to be involved in malignant progression of gliomas and carries mutations in families with autosomal dominant lateral temporal epilepsy (ADLTE), a rare familial partial epilepsy syndrome. This gene was found to be frequently downregulated and sometimes rearranged in malignant gliomas (Chernova et al. 1998) , suggesting a possible tumor suppression function. However, neither point mutations of the coding region nor differential methylation of the LGI1 core promoter region have been demonstrated in these tumors (Somerville et al. 2000) , arguing against a role of LGI1 as a tumor suppressor gene. Recent studies have suggested that LGI1 may have a role in gliomagenesis as a tumor metastasis suppressor gene (Kunapuli et al. 2003; Kunapuli et al. 2004) .
ADLTE, also known as autosomal dominant partial epilepsy with auditory features (ADPEAF), has been recognized as a distinct epileptic condition characterized by typical auditory auras and/or symptoms suggesting a lateral temporal onset, absence of any brain structural abnormality, and benign evolution. Recently, we and others have identified mutations causing ADLTE in LGI1 (Kalachikov et al. 2002; Morante-Redolat et al. 2002) . Numerous additional LGI1 mutations resulting in either protein truncation or single amino acid substitutions have been reported subsequently (see Ottman et al. 2004) , including a de novo mutation (Bisulli et al. 2004) . Overall,
LGI1 mutations have been found in about 50% of ADLTE families (Michelucci et al. 2003; Ottman et al. 2004; Berkovic et al. 2004) .
LGI1, which has been renamed Epitempin, is mostly expressed in the brain (Chernova et al. 1998) .
In situ hybridisation experiments have shown that expression of the orthologous murine gene is predominantly neuronal (Kalachikov et al. 2002) . Both in humans and mice, the main transcription product is predicted to encode a protein of 557 amino acids. Computer analysis of the amino acid sequence has identified an amino-terminal signal peptide sequence and two distinct structural domains, each spanning about half of the protein. The N-terminal half of the protein consists of 3.5 Furlan et al. 5 leucine-rich repeat (LRR) sequences flanked on both sides by typical cysteine-rich repeat sequence clusters (Kobe and Kajava 2001) ; the C-terminal half is made of seven copies of a novel repeat of about 45 residues, named epitempin (EPTP; Staub et al. 2002) or epilepsy associated region (EAR; Scheel et al. 2002) , which is reminiscent of the beta-propeller structural domain (Paoli 2001) . The same structural disposition of LRR and EPTP/EAR domains has been identified in three putative paralogues, named LGI2, LGI3, and LGI4 (Gu et al. 2002; Staub et al. 2002; Scheel et al. 2002) .
LRR and beta-propeller motifs are found in many other proteins and often mediate protein-protein interactions.
Functional studies of LGI1/Epitempin are still at early stage. Particularly, the biochemical features, subcellular localization, and distribution in brain tissues of the protein product have not yet been characterized. A few studies have investigated LGI1/Epitempin protein expression in human and mouse brain by immunohistochemistry (Gu et al. 2002; Morante-Redolat et al. 2002) , but signal specificity of the polyclonal antibodies utilized was poorly characterized.
In this study, we characterized the basic biochemical features of the LGI1/Epitempin protein product and investigated its subcellular localization and distribution in various regions of the human brain by Western blot analysis.
Materials and methods

Materials
Reagents for sodium dodecylsulfate-polyacrilamide gel electrophoresis (SDS-PAGE) were purchased from Mallinckrodt Baker (Phillipsburg, NJ, USA). Molecular mass standards for SDS-PAGE (phosphorylase B, albumin, ovalbumin, carbonic anhydrase, trypsin inhibitor, and α-lactalbumin, Mr 97, 66, 45, 30, 20, 1, and 14, 4 kDa, respectively) , enhanced chemiluminescence (ECL) Western Blotting Detection Reagents, and autoradiography film were from Amersham Biosciences (Piscataway, NJ, USA). Phenylmethyl-sulfonyl fluoride (PMSF), benzamidine, Furlan et al. 6 leupeptin, bovin serum albumin, EGTA, sucrose, HEPES, 5-bromo-4-chloro-3-indolyl phosphate (BCIP) liquid substrate system, nitro blue tetrazolium (NBT), and anti-mouse IgG conjugated to alkaline phosphatase secondary antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA). Nitrocellulose was from Sartorius (Hamburg, Germany). Anti-rabbit and anti-goat IgG conjugated to horseradish peroxydase secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Dulbecco's Modified Eagle's Medium (DMEM) and fetal bovine serum 
Antibodies
Six polyclonal antibodies raised against different LGI1/Epitempin peptides were tested: the commercially available antibodies sc-9583, sc-9581, and sc-28238 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); a rabbit antiserum developed by Kunapuli and co-workers (2003) (generous gift of Dr. J. K. Cowell); and two additional antisera developed by us (see Morante-Redolat et al. 2002) . A mouse monoclonal antibody to glyceraldehyde-3phosphate dehydrogenase (GAPDH) was from Chemicon (Temecula, CA, USA).
Mouse tissue preparation
Adult mice (strain C57BL/6J) were used as a source of brain, skeletal muscle, heart, kidney, spleen, and liver. Tissues were frozen immediately in liquid nitrogen and stored at -80°C until use. Whole homogenates were prepared as described previously (Salvatori et al. 1997) . Briefly, tissues were homogenized by using an Ultraturrax disperser (20,000 RPM) in the presence of a medium containing 3% (wt/vol) sodium dodecylsulfate (SDS), 0,1 mM EGTA, pH 7.0 and a protease inhibitor mixture (PMSF and benzamidine 1 mmol/l, leupeptin 0,1 mmol/l). Homogenates were then boiled for 5 min and clarified at 15,000xg for 10 min. Supernatants were used as whole protein extracts. Furlan et al. 7 For mouse brain fractionation all steps were carried out at 4°C. Brains from adult mice were homogenized in 0,32 M sucrose, 10 mM HEPES-KOH, pH 7.4 at 4 ml/g of tissue in the presence of the above protease inhibitor mixture to minimize protein degradation by using an Ultraturrax disperser (13,500 RPM). A post-nuclear supernatant was prepared by centrifugation of the homogenate at 3,000xg for 10 mins, and spinned again at 25,000xg for 10 mins. A crude membrane fraction was separated from the cytosolic fraction by centrifuging the last supernatant at 35,000xg or 105,000xg for 1 hr. The resulting pellet (microsomal fraction) was resuspended in RIPA buffer (50mM Tris-HCl pH 8.0, 0.15 M NaCl, 1% (vol/vol) Nonidet P-40, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS).
.
Human brain tissue preparation
Fresh tissue samples of grey matter from superior frontal gyrus, post-central (parietal) cortex, superior temporal gyrus, primary visual (occipital) cortex, and samples from anterior superior cerebellar vermis, hippocampus (Ammon's horn) and putamen were taken from brains of an Italian 80-year-old male (subject 1) died of heart stroke and a British 70-year-old female (subject 2) died of lung carcinoma at the Institute of Anatomic Pathology, Bellaria Hospital, Bologna, Italy and the UK Multiple Sclerosis Tissue Bank, respectively. Sampling was performed 12 hours post-mortem.
Neuropathological examination did not reveal significant pathological abnormalities but ageing changes consisting of a few diffuse senile plaques in the frontal and hippocampal cortex.
Particularly, no metastatic deposits were seen in the brain from subject 2. After removing leptomeninges, cortical ribbon was dissected using a magnification lens in order to avoid any contamination or white matter. Tissues were frozen in liquid nitrogen straight after sampling and then stored at -70°C. Whole protein homogenates were obtained as described for mouse tissues. Furlan et al. 8 Human embryonic kidney 293 (HEK293) cells were grown in 4 ml DMEM plus 10% (vol/vol) FBS on 25 cm 2 flasks and transfected with a pcDNA3LGI1 expression construct using Lipofectamine 2000, following the manufacturer instructions. Twenty-four hours after the beginning of transfection cells were washed twice and then re-fed with 4 ml of serum-free medium Opti-MEM.
Cell culture transfection assay
Cells were kept in serum-free medium for about 20 hours. The medium was then collected and centrifuged to pellet cell debris, after which the supernatant was concentrated to about 100 µl using Centricon YM30 concentrators (Millipore, Billerica, MA, USA). Twenty-five µl of the concentrated medium were loaded on an SDS-PAGE gel and analysed by Western blot. In parallel, we also loaded a similarly concentrated medium obtained from cells transfected with pcDNA3 vector alone or a green fluorescent protein (GFP) expression construct. Cell extracts were prepared for immunoblotting using Triton lysis buffer ( 25 mM Tris pH 7.4, 150 mM NaCl, 1% (vol/vol) Triton, 10% (vol/vol) Glycerol, 1mM EDTA) supplemented with proteases inhibitors (Leupeptin 10 µg/ml, Aprotinin 10 µg/ml, PMSF 1mM) and phosphatase inhibitors (20mM NaF, 20 mM Na 2 VO 3 , β-glycerophosphate).
Protein analysis
Protein concentration was determined as described by Bradford (1976) 
Mass spectrometry analysis
Mouse microsomal and cytosolic fraction proteins and HEK293-LGI1 medium proteins were resolved by standard SDS-PAGE prior to cutting the relevant lanes of the gel into slices. Those slices corresponding to the regions of immunoreactivity with sc-9583 were then subjected to mass spectrometry analysis together with control slices. Following de-staining, gel slices were washed with 50 mM ammonium bicarbonate and shrinked with ethanol. Reduction/alkylation of proteins was performed with 10 mM dithiothreitol (DTT) and 55 mM iodoacetamide. After two wash steps with ammonium bicarbonate/ethanol, the gel was dried with ethanol and incubated with 12.5 ng/µl trypsin in 50 mM ammonium bicarbonate at 4°C for 15 min. The supernatant was then replaced with fresh 50 mM ammonium bicarbonate and the reaction allowed to proceed overnight at 37°C. modifications. The mass error of all the identified peptides was below 1 parts per million (ppm) and these peptides were matched with the highest score to the LGI1 sequence ("bold red" in Mascot).
Results
Immunoblot analysis of mouse tissues
In humans and mice, the LGI1/Epitempin protein product is highly conserved (97% identity) and has an expected molecular mass of 64 kDa. We tested six polyclonal antibodies raised against
LGI1/Epitempin peptides (see Materials and Methods) by Western blot analysis of whole cell extracts from mouse brain. Five of these antibodies detected weak or no bands around 60 kDa (data not shown). The commercially available antibody sc-9583 detected two bands at about 60 and 65 kDa, the 60-kDa product being far more abundant (Fig. 1 A) . None of these bands was detected in other mouse tissues (Fig. 1 A) , and detection of both proteins was abolished by blocking the primary antibody with the peptide used for immunization (not shown). An additional protein of about 22 kDa was recognized only in mouse skeletal muscle (Fig. 1 A) , which may represent a muscle-specific isoform or a cross-reaction product.
Differential centrifugation of mouse brain homogenates
To investigate the subcellular localization of the two brain-specific proteins, we performed immunoblot analysis of crude microsomal and cytosolic fractions obtained by differential centrifugation of whole mouse brain homogenates. The sc-9583 antibody detected the 60-kDa protein exclusively in the microsomal fraction, whereas the 65-kDa product was found in the cytosolic fraction, where it was considerably enriched (Fig. 1 B) . Western blots of microsomal and cytosolic fractions were then probed with the other five anti-LGI1 antibodies. The rabbit antiserum developed by Kunapuli and colleagues (2003) detected a band of about 65 kDa in the cytosolic fraction exactly co-migrating with the cytosolic protein identified by sc-9583, whereas no bands Furlan et al. 11 were noted in the microsomal fraction (Fig. 2) . Although it cross-reacted with other proteins of various molecular masses, this antiserum was previously shown to recognize an LGI1-specific polypeptide in extracts from glioblastoma cell lines stably transformed with an LGI1-FLAG construct (Kunapuli et al. 2003) . Therefore, both Kunapuli's and sc-9583 antibodies very likely recognized the same 65-kDa cytosolic protein that was encoded by LGI1.
Cell culture expression of LGI1/Epitempin
The proteins expressed by HEK293 cells transiently transfected with an LGI1/Epitempin expression construct were analysed by immunoblotting. Both cell lysate and concentrated (about 40x) serumfree medium were analysed using the sc-9583 antibody. In the medium, this antibody detected a band similar in size to the 60-kDa protein recognized in mouse brain (Fig. 3) . No such band was detected in the lysate of LGI1-transfected cells or in the medium of HEK293 cells transfected with a GFP expression construct as control. The specificity of the protein seen in the medium of LGI1-transfected cells was confirmed by mass spectrometry analysis: several LGI1-specific peptides were identified in a gel-fractionated medium protein sample corresponding to the band immunoreacting with the sc-9583 antibody, altogether spanning 28% of the LGI1/Epitempin protein length (see Supplementary Table S3) . Thus, our results show that the LGI1/Epitempin protein produced in transfected HEK293 cells is secreted, confirming the data published recently by Senechal and co-
workers (2005).
Mass spectrometry analysis of mouse brain proteins
To gain further, more direct, evidence for the specificity of both the 60 and 65 kDa products to
LGI1/Epitempin, we analysed gel-fractionated mouse brain proteins by mass spectrometry. Protein samples resolved by SDS-PAGE and corresponding to the microsomal and cytosolic bands recognized by the sc-9583 antibody were cut out of gel, digested with trypsin and analyzed (see Materials and Methods). Several LGI1-specific peptides were identified in both samples, spanning Furlan et al. 12 25% and 15% of the microsomal and cytosolic protein forms, respectively ( Fig. 4 ; details in Supplementary Tables S1 and S2 ). This finding combined with the results described above strongly suggest that the two products recognized by the sc-9583 antibody are protein isoforms encoded by
LGI1/Epitempin.
Immunoblot analysis of human brain tissues
To check whether the two proteins detected in the mouse brain by sc-9583 were also expressed in the human brain, we performed Western blot analysis of samples of grey matter taken from postmortem brains of two individuals with no neurological diseases. Tissue samples from cortical areas of the frontal, parietal, occipital, and temporal lobes, and from cerebellum, hippocampus, and putamen were analysed. Tissue extracts subjected to immunoblot contained comparable amounts of total proteins, as determined by Red Ponceau staining and immunostaining with anti-GAPDH antibody (Fig. 5 B) . Both the 60-and 65-kDa proteins were shown by the sc-9583 antibody in most human brain samples, and, as in the mouse, the 60-kDa product was found to be more abundant than that of 65 kDa (Fig. 5 A) . Expression of the two proteins was considerably different in the various tissue samples from the two individuals analysed (Fig. 5 A) . The 65-kDa protein was absent in the cerebellum and was barely detectable in the occipital cortex and hippocampus; higher amounts were observed in the parietal and frontal cortices, putamen, and, particularly, in the temporal neocortex, where this protein was 3 to 5 times more abundant than in the hippocampus, as
shown by densitometry (data not shown). Variations in abundance of the 60-kDa product were also considerable in some samples (Fig. 5 A) , the highest expression level occurring in the occipital cortex and the lowest in the hippocampus (2:1 densitometric ratio; data not shown). Although some differences in expression pattern were seen, particularly in the cerebellum, comparable band intensities were observed in most tissue samples from the two individuals analysed, suggesting that the expression variations seen in different brain regions were site-specific. LGI1/Epitempin cDNA. Here, we confirm this result and show that the soluble LGI1/Epitempin protein secreted by transfected HEK293 cells seems to correspond to the 60-kDa product detected in brain tissues (Fig. 3 ). Yet, the latter protein was found only in the membrane-enriched fraction and not in the soluble fraction obtained from mouse brain tissues. A possible explanation for this is that the 60-kDa LGI/Epitempin product, once secreted outside brain cells, binds to other proteins to form a protein complex bound to membrane structures. Alternatively, this protein may undergo Northern blot analysis has revealed that LGI1/Epitempin is widely expressed in the human brain, though with varying intensity in different brain regions (Chernova et al. 1998) . In addition, in situ hybridisation experiments have shown that expression of the murine LGI1 gene is higher in some areas, particularly in the neocortex and limbic regions (Kalachikov et al. 2002; Senechal et al. 2005) . In keeping with mRNA expression studies, our immunoblotting data clearly showed variable expression of both LGI1/Epitempin proteins in the human brain regions investigated, suggesting that expression of the LGI1/Epitempin gene may be differentially regulated in different brain regions and that such tissue-specific expression may affect neuronal function. Notably, the abundance of the 65-kDa LGI1/Epitempin product was much higher in the lateral temporal cortex than in the hippocampus, where this protein species was barely detectable; the 60-kDa product also appeared to be more expressed in the temporal neocortex than in the hippocampus, though the (Battye et al. 2001; Wu et al. 1999) , then the LGI1/Epitempin products, once secreted, are likely to exert their action locally.
In conclusion, we have identified two protein products very likely encoded by LGI1/Epitempin, which are differentially expressed in the temporal cortex, consistent with the lateral temporal localization of seizures in patients with LGI1/Epitempin mutations. Further work is needed to clarify their biochemical differences, and to determine their fine distribution across the human brain.
While this paper was under revision, Schulte and co-workers (2006) showed that an LGI1 protein product of about 60 kDa is complexed with Kv1.1 potassium channels in neurons of rat hippocampus. This protein, the single product recognized by an anti-LGI1 antibody developed by these authors, was found in the membrane-enriched fraction obtained from rat brain homogenate and was shown to be associated to the neuronal membrane possibly through protein-protein Furlan et al. 16 interactions. Because of its molecular mass and subcellular localization, the protein described by Schulte and co-workers very likely corresponds to the 60-kDa LGI1 isoform recognized by the sc-9583 antibody. 
